Article ; Online: Role of interleukin 6 signaling pathway in the anti-inflammatory effects of statins on coronary artery disease: Evidence from Mendelian randomization analysis.
International journal of cardiology
2024 Volume 406, Page(s) 131964
Abstract: Background: Statins are currently widely used in the prevention of coronary artery disease (CAD) primarily for lipid-lowering with a potential anti-inflammatory effect. However, it is not clear if their potential anti-inflammatory effects are mediated ... ...
Abstract | Background: Statins are currently widely used in the prevention of coronary artery disease (CAD) primarily for lipid-lowering with a potential anti-inflammatory effect. However, it is not clear if their potential anti-inflammatory effects are mediated through the interleukin 6 (IL-6) signaling pathway. Methods: Using the Mendelian randomization (MR) approach followed by multivariable MR analyses, we examined the extent to which the effects of statins on CAD might be mediated through the IL-6 signaling pathway. Results: Our observations showed that HMG-CoA reductase, using LDL levels as a proxy, had a significant effect on upstream IL-6 (βMR = 0.47, P-IVW = 0.01) and nominally significant effects on IL-6RA (βMR = 0.22, P-IVW = 0.047) and APOB (βMR = 0.82, P-IVW = 1.8 × 10-33). While the IL-6 signaling cascade (IL-6RA βMR = -0.06, P-IVW = 3.45 × 10-20 and IL-6 βMR = -0.03, P-IVW = 0.09) and the anti-inflammatory effect of HMG-CoA reductase (βMR = -0.31, P-IVW = 0.01) was found to influence the risk of CAD, the multivariable MR (MVMR) model indicated that the anti-inflammatory effect of HMG-CoA reductase is not likely to be mediated through the IL-6 signaling cascade, including APOB and IL-6RA (MVMRβ = 0.23, P = 0.688). Conclusions: Our findings suggest that statins may use inflammatory mechanisms independent of the IL-6 signaling pathway to prevent CAD. This result could potentially affect the definition of the target population for statin use. |
---|---|
MeSH term(s) | Mendelian Randomization Analysis ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Humans ; Interleukin-6/metabolism ; Interleukin-6/blood ; Coronary Artery Disease/genetics ; Coronary Artery Disease/blood ; Coronary Artery Disease/drug therapy ; Signal Transduction/drug effects ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Polymorphism, Single Nucleotide |
Chemical Substances | Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Interleukin-6 ; Anti-Inflammatory Agents ; IL6 protein, human |
Language | English |
Publishing date | 2024-03-19 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 779519-1 |
ISSN | 1874-1754 ; 0167-5273 |
ISSN (online) | 1874-1754 |
ISSN | 0167-5273 |
DOI | 10.1016/j.ijcard.2024.131964 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1673: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.